Anthracyclines have been important and effective treatments against a number of cancers
since their discovery. However, their use in therapy has been complicated by severe side …

Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

Introduction Multi-drug resistance (MDR) is a hindrance toward the successful treatment of
cancers. The primary mechanism that gives rise to acquired chemoresistance is the …

Chemoresistance has remained a significant concern in tumor recurrence and elevated
cancer-related mortalities. A deep insight into mechanisms by which cancerous cells resist …

Multidrug resistance (MDR) seriously limits the clinical application of chemotherapy. A
mechanism underlying MDR is the overexpression of efflux transporters associated with …

Mesenchymal stem cells (MSCs)-derived exosomes were considered a novel therapeutic
approach in many aging-related diseases. This study aimed to clarify the protective effects of …

Considering the fact that cancer cells can switch among various molecular pathways and
mechanisms to ensure their progression, chemotherapy is no longer effective enough in …

Cancer drug resistance poses a significant obstacle to successful chemotherapy, primarily
driven by the activity of ATP‐binding cassette (ABC) transporters, which actively efflux …

Cancer is frequently caused by microRNAs, which control post-transcriptional levels of gene
expression by binding to target mRNAs. MiR-29a-3p has recently been shown to play a …

Multidrug resistance (MDR) is one of the primary factors that produces treatment failure in
patients receiving cancer chemotherapy. MDR is a complex multifactorial phenomenon …